Goldman Sachs resumed coverage of Immunovant (IMVT) with a Neutral rating and $18 price target The firm sees limited downside but also a challenging regulatory backdrop for the company.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease
- 3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts
- Immunovant’s Promising Clinical Trials and Strategic Drug Focus Justify Buy Rating
- Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position
- Immunovant price target lowered to $35 from $51 at H.C. Wainwright